The following information is exclusively reserved for physicians practicing in Austria, the Netherlands, Spain, and Switzerland where the Zio™ monitor ECG monitoring service is currently authorised and made available for use in accordance with local regulatory requirements.

Learn more
Search

The Total Package

The right mix of clinical accuracy,1-3 outstanding patient compliance,2-4 and elegant implementation.

Physician talking with patient

Advanced monitors

Our Zio™ monitor is designed with patients in mind5, resulting in astounding 99% patient compliance with prescribed wear times.,2-4 This long-term continuous monitoring (LTCM) service enables continuous, uninterrupted recording and a comprehensive end-of-wear report.5

Efficient solutions

Improve scalability and access to healthcare by integrating the Zio™ service directly into your EHR via HL7 or the Epic Aura network. In addition, with the ZioSuite clinician portal, you can efficiently manage your patient monitoring workflow from device registration and tracking to report interpretation.20

Exceptional accuracy

The Zio™ service is associated with the highest diagnostic yield and the lowest likelihood of repeat testing compared to 48-hour (traditional) Holter, 1-3,6-11 and includes a comprehensive end-of-wear report with 99% physician agreement 2-3,12. Providing you with highly accurate data you can trust, so you can make the right diagnosis first time.1-3
Physician showing information to patient

An end-to-end cardiac monitoring service

The iRhythm monitoring service provides you with everything your department needs. From our advanced, yet simple-to-use Zio™ ECG monitors2,18-19 to our elegant data management solutions, we are transforming the world of cardiac monitoring with every heartbeat.2-3,6-11

Explore the iRhythm service
User researching iRhythm on computer

CE-marked and FDA-cleared Advanced AI with a human touch

Our CE-marked and FDA-cleared Zio™ ECG Utilization Service (ZEUS) System deep learned algorithm is proven to be as accurate as expert cardiologists,13-16, enabling you to confidently diagnose arrhythmias, including atrial fibrillation.8-9,17 The iRhythm monitoring service delivers accurate and succinct reports1-3 that are curated and verified by our Qualified ECG Specialists (QES).13-16

Continue the conversation

The Zio™ Service helps you detect arrhythmias earlier, reduce administrative burden, and enhance patient experience — all through a single, streamlined platform.

 

Connect with an iRhythm specialist today to discover how the Zio™ Service can fit into your workflow.

Continue the conversation
Man with child on his shoulders
  1. Data on file. iRhythm Technologies, 2022-2023. 
  2. Based on the US market data using Zio ECG monitors. 
  3. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report. 
  4. Data on file. iRhythm Technologies, 2022.  
  5. Zio monitor Instructions for Use. iRhythm Technologies, 2023. 
  6. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25–34. https://doi.org/10.1016/j.ahj.2023.12.002 
  7. Diagnostic yield was assessed based upon the evaluation of specified arrhythmias, which refer to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.  
  8. Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file. 
  9. Zio LTCM service refers to Zio XT and Zio monitor service. 
  10. Contraindications: Do not use the Zio monitor for critical care patients or for patients with symptomatic episodes where instance variations in cardiac performance could result in immediate danger to the patients or when real-time or in-patient monitoring should be prescribed. (Refer to the Zio monitor Instructions for Use for the full list of contraindications.) 
  11. Zio monitor and ZEUS are CE-marked. 
  12. 99% of physicians agree with the comprehensive end-of-wear report. Based on a review of all online Zio XT, Zio monitor, and Zio AT end-of-wear reports. Data on file. iRhythm Technologies, 2023. 
  13. Data on file. iRhythm Technologies, 2020. 
  14. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. https://doi.org/10.1038/s41591-018-0268-3
  15. Deep learned algorithm is only available in the United States, European Union, Switzerland, United Kingdom, and Japan.  
  16. FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval. 
  17. Rosenberg et al. Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: A Pilot Study. Pacing and Clinical Electrophysiology. 2012;36(3):328-333. doi:https://doi.org/10.1111/pace.12053
  18. Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717
  19. Data on file. iRhythm Technologies, 2024
  20. ZioSuite Clinical Reference Manual. iRhythm Technologies.

 

The Zio™ service is a long-term continuous ambulatory cardiac monitoring service. It consists of the Zio™ monitor that collects beat-to-beat ECG data and can be worn for up to 14 days; the Zio™ ECG Utilization Service (ZEUS) System deep learned algorithm, which detects arrhythmias. The data is reviewed and curated by a team of Qualified ECG Specialists (QES) to provide the final patient report.

 

For indications for use, warnings & contraindications, visit here.

 

iRhythm, Zio, Zio monitor and ZioSuite are trademarks of iRhythm Technologies, Inc. ©2024 All rights reserved.

 

Zio™ monitor and ZEUS are CE-marked (CE2797).

 

Zio monitor, ZEUS and Zio service are currently available in Austria, Netherlands, Spain & Switzerland.

 

For further regulatory information visit here.

 

WEB0204.01